The R-Pharm Group of Companies presented the preliminary results of the trial of its original Goflikicept drug at the Annual European Congress of Rheumatologists EULAR 2022, the largest specialized research conference. In the course of a phase II/III clinical trial of Goflikicept in the treatment of patients with idiopathic recurrent pericarditis, all the declared efficacy endpoints were achieved.
Arcerix (Goflikicept), formerly known as the RPH-104 molecule, is a biological drug developed in R-Pharm’s laboratory, a new heterodimeric protein that inhibits IL-1. It is being developed for the treatment of diseases that involve systemic inflammation, including myocardial infarction, Schnitzler syndrome, COVID-19, recurrent pericarditis, familial Mediterranean fever and Still’s disease.
“The fact that the report on Goflikicept was chosen by the organizers of EULAR 2022 for presentation during the main scientific session in the most prestigious, oral format, once again underlines the importance of our research program. Its preliminary results are encouraging and bring the scientific community closer to victory over such a dangerous and complex disease as idiopathic recurrent pericarditis,” Mikhail Samsonov, Medical Director of R-Pharm, said.
R-Pharm also presented a series of reports on Olokizumab at the largest conference of European rheumatologists.
